Anna Guidetti
University of Milan
Internal medicineSurgeryOncologyImmunologyPerifosineChemotherapyNeutropeniaCytarabineDiffuse large B-cell lymphomaSorafenibProgressive diseaseLymphomaBone marrowRituximabTransplantationNuclear medicineHodgkin lymphomaPhases of clinical researchRefractoryCancer researchMedicineBiologyGastroenterology
84Publications
16H-index
789Citations
Publications 83
Newest
#1Anna GuidettiH-Index: 16
#2Anna DoderoH-Index: 21
Last. Alessandra AlessiH-Index: 11
view all 0 authors...
Source
#1Annalisa ChiappellaH-Index: 29
#2Anna GuidettiH-Index: 16
Last. Patrizia Chiusolo (UCSC: Catholic University of the Sacred Heart)H-Index: 32
view all 0 authors...
Source
#1Reid W. Merryman (Harvard University)H-Index: 11
#2Luca CastagnaH-Index: 35
Last. Carmelo Carlo-Stella (Humanitas University)H-Index: 43
view all 66 authors...
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent all...
Source
#1Alessandra TucciH-Index: 36
#2Alessandro ReH-Index: 21
Last. Giuseppe RossiH-Index: 69
view all 17 authors...
Source
Source
#1Annalisa ChiappellaH-Index: 29
#2Anna DoderoH-Index: 21
Last. Paolo Corradini (University of Milan)H-Index: 93
view all 13 authors...
Source
#1Chiara RusconiH-Index: 19
view all 11 authors...
Source
#1Chiara OltoliniH-Index: 8
#2Anna GuidettiH-Index: 16
Last. Fabio CiceriH-Index: 84
view all 18 authors...
1 CitationsSource
#1Simonetta VivianiH-Index: 33
#2Arabella MazzocchiH-Index: 10
Last. Alessandro Rambaldi (University of Milan)H-Index: 114
view all 21 authors...
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples,...
1 CitationsSource
#1Simonetta VivianiH-Index: 33
#1S. VivianiH-Index: 9
Last. Alessandro RambaldiH-Index: 17
view all 21 authors...
Source